Otonomy (OTIC) Announces Completion of OTIPRIO Phase 2 in AOMT; Stat. Significant Data Noted
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Otonomy, Inc. (Nasdaq: OTIC) announced the successful completion of a Phase 2 clinical trial that evaluated a single administration of OTIPRIO (ciprofloxacin otic suspension) for the treatment of pediatric patients with acute otitis media with tympanostomy tubes (AOMT). The Phase 2 trial was designed to evaluate the safety and tolerability of two dose levels of OTIPRIO, 6 mg (0.1 mL) and 12 mg (0.2 mL), administered in pediatric patients with AOMT and to determine the most appropriate dose for further development in this indication. The trial demonstrated that both OTIPRIO doses were well-tolerated, achieved higher and statistically significant (p<0.05) clinical cure rates over sham (no treatment), with the highest clinical cure rate observed in the 12 mg dose group.
Additional results from this trial will be presented at the Otonomy Investor and Analyst Day on October 7 and will be presented at an upcoming medical conference.
“This study builds on the prior Phase 2 trial, which established the feasibility of administering OTIPRIO in an awake child in the physician office setting, by demonstrating that the preferred dose for further development in AOMT is 12 mg,” said David A. Weber, Ph.D., president and CEO of Otonomy. “Furthermore, we believe that achieving statistical significance in the clinical cure rate versus sham, with a relatively small number of subjects in this study, establishes a favorable benchmark for sizing a successful registration program for OTIPRIO in AOMT. We intend to meet with the FDA to discuss the requirements for such a program following our completion of the ongoing Phase 3 registration trial in acute otitis externa, the first label expansion indication for OTIPRIO."
The one-month, prospective, randomized, sham-controlled, blinded Phase 2 clinical trial enrolled 95 pediatric patients with unilateral or bilateral AOMT at 12 centers in the United States. The trial was designed to evaluate the safety, tolerability, and comparative clinical activity of two dose levels of OTIPRIO, 6 mg (0.1 mL) and 12 mg (0.2 mL), when administered as a single treatment in the physician’s office. Clinical activity was primarily assessed at Day 15 based on clinical cure rate defined as resolution of otorrhea determined by the physician through an otoscopic examination.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Merus N.V. (MRUS) Enters Strategic Research Collaboration with Incyte (INCY); Includes Upfront Payment of $120M
- Minerals Technologies (MTX) Elects Matthew Garth as CFO
- Eyegate Pharma (EYEG) Granted Canadian Patent for Proprietary Iontophoretic Formulation and Use
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!